Urogenital Abnormalities in Adenosine Deaminase Deficiency.
Adenosine Deaminase
/ genetics
Adolescent
Agammaglobulinemia
/ genetics
Child
Child, Preschool
Female
Humans
Infant
Infant, Newborn
Male
Puberty
Retrospective Studies
Severe Combined Immunodeficiency
/ genetics
Sexual Development
/ physiology
Urogenital Abnormalities
/ genetics
Urogenital System
/ physiology
ADA-SCID
cryptorchidism
pubertal development
puberty
undescended testis
urogenital abnormalities
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
30
11
2019
accepted:
30
03
2020
pubmed:
21
4
2020
medline:
7
8
2021
entrez:
21
4
2020
Statut:
ppublish
Résumé
Improved survival in ADA-SCID patients is revealing new aspects of the systemic disorder. Although increasing numbers of reports describe the systemic manifestations of adenosine deaminase deficiency, currently there are no studies in the literature evaluating genital development and pubertal progress in these patients. We collected retrospective data on urogenital system and pubertal development of 86 ADA-SCID patients followed in the period 2000-2017 at the Great Ormond Street Hospital (UK) and 5 centers in Italy. In particular, we recorded clinical history and visits, and routine blood tests and ultrasound scans were performed as part of patients' follow-up. We found a higher frequency of congenital and acquired undescended testes compared with healthy children (congenital, 22% in our sample, 0.5-4% described in healthy children; acquired, 16% in our sample, 1-3% in healthy children), mostly requiring orchidopexy. No urogenital abnormalities were noted in females. Spontaneous pubertal development occurred in the majority of female and male patients with a few cases of precocious or delayed puberty; no patient presented high FSH values. Neither ADA-SCID nor treatment performed (PEG-ADA, BMT, or GT) affected pubertal development or gonadic function. In summary, this report describes a high prevalence of cryptorchidism in a cohort of male ADA-SCID patients which could represent an additional systemic manifestation of ADA-SCID. Considering the impact urogenital and pubertal abnormalities can have on patients' quality of life, we feel it is essential to include urogenital evaluation in ADA-SCID patients to detect any abnormalities, initiate early treatment, and prevent long-term complications.
Sections du résumé
BACKGROUND
Improved survival in ADA-SCID patients is revealing new aspects of the systemic disorder. Although increasing numbers of reports describe the systemic manifestations of adenosine deaminase deficiency, currently there are no studies in the literature evaluating genital development and pubertal progress in these patients.
METHODS
We collected retrospective data on urogenital system and pubertal development of 86 ADA-SCID patients followed in the period 2000-2017 at the Great Ormond Street Hospital (UK) and 5 centers in Italy. In particular, we recorded clinical history and visits, and routine blood tests and ultrasound scans were performed as part of patients' follow-up.
RESULTS AND DISCUSSION
We found a higher frequency of congenital and acquired undescended testes compared with healthy children (congenital, 22% in our sample, 0.5-4% described in healthy children; acquired, 16% in our sample, 1-3% in healthy children), mostly requiring orchidopexy. No urogenital abnormalities were noted in females. Spontaneous pubertal development occurred in the majority of female and male patients with a few cases of precocious or delayed puberty; no patient presented high FSH values. Neither ADA-SCID nor treatment performed (PEG-ADA, BMT, or GT) affected pubertal development or gonadic function.
CONCLUSION
In summary, this report describes a high prevalence of cryptorchidism in a cohort of male ADA-SCID patients which could represent an additional systemic manifestation of ADA-SCID. Considering the impact urogenital and pubertal abnormalities can have on patients' quality of life, we feel it is essential to include urogenital evaluation in ADA-SCID patients to detect any abnormalities, initiate early treatment, and prevent long-term complications.
Identifiants
pubmed: 32307643
doi: 10.1007/s10875-020-00777-8
pii: 10.1007/s10875-020-00777-8
pmc: PMC7253380
doi:
Substances chimiques
Adenosine Deaminase
EC 3.5.4.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
610-618Subventions
Organisme : Department of Health
Pays : United Kingdom
Références
Bone Marrow Transplant. 2017 Jul;52(7):1029-1035
pubmed: 28287638
J Clin Immunol. 2017 Aug;37(6):582-591
pubmed: 28748310
J Clin Immunol. 2017 Oct;37(7):626-637
pubmed: 28842866
Biol Blood Marrow Transplant. 2019 Sep;25(9):1786-1791
pubmed: 31082473
Nat Rev Dis Primers. 2019 May 30;5(1):38
pubmed: 31147553
J Pediatr Urol. 2012 Feb;8(1):2-6
pubmed: 21497555
FASEB J. 2016 Jan;30(1):3-12
pubmed: 26333425
Orphanet J Rare Dis. 2018 Apr 24;13(1):65
pubmed: 29690908
Adv Immunol. 2005;86:1-41
pubmed: 15705418
J Clin Invest. 2008 Apr;118(4):1491-501
pubmed: 18340377
J Allergy Clin Immunol. 2019 Mar;143(3):852-863
pubmed: 30194989
Front Immunol. 2016 Aug 16;7:314
pubmed: 27579027
Front Pediatr. 2019 Sep 24;7:381
pubmed: 31616648
Blood. 2019 Jun 6;133(23):2546-2549
pubmed: 30952673
Curr Opin Pediatr. 2016 Jun;28(3):388-94
pubmed: 27138807